Table 2. Downregulation of human SPARCL1 in malignant carcinomas.
| Healthy tissue | Malignant carcinoma | |||
|---|---|---|---|---|
| IHC | Cellular location | IHC | Cellular location | |
| Oesophagus | ++ | EC, MC, epithelium, SMC | ++ | EC, MC |
| Stomach | +++ | EC, MC, SMC | ++ | EC, MC |
| Small intestine | ++ | EC, MC, SMC | ++ | EC, MC |
| Large intestine | +++ | EC, MC, SMC | ++ | EC, MC, SMC |
| Pancreas | +++ | EC, MC, islet cells | ++ | EC, MC |
| Liver | ++ | MC, hepatocytes | ++ | MC, hepatocytes |
| Lung | +++ | EC, MC, around bronchial tubes, alveolar tissue | ++ | EC, MC, alveolar tissue |
IHC, immunohistochemistry
EC, endothelial cells; MC, mural cells; SMC, smooth muscle cells
+++, strong expression; ++, intermediate expression; +, weak expression